ARR880315 Supplemental Material - Supplemental material for The future of breast cancer screening: what do participants in a breast cancer screening program think about automation using artificial intelligence?

Supplemental material, ARR880315 Supplemental Material for The future of breast cancer screening: what do participants in a breast cancer screening program think about automation using artificial intelligence? by Olof Jonmarker, Fredrik Strand, Yvonne Brandberg and Peter Lindholm in Acta Radiologica Open</p

QLQ-C30 scale scores by participation to risk-based PC screening, three months before invitation to screening.

QLQ-C30 scale scores by participation to risk-based PC screening, three months before invitation to screening.</p

High levels of health-related quality of life five years after curative treatment of prostate cancer with HDR-brachytherapy and external beam radiation

The aim of this cross-sectional study was to investigate long-term health-related quality of life (HRQoL) in men with prostate cancer treated 2002–2008 with external beam radiotherapy (EBRT) combined with high dose-rate brachytherapy (HDRBT), Cohort A, and to compare these data with age-adjusted normative data. In addition, differences in HRQoL following adjustments of the brachytherapy technique in 2001 were investigated by comparing Cohort A with men treated at the same clinic from 1998-2000, Cohort B. Cohort A: 1495 men treated with EBRT 2 Gy to 50 Gy and 2 fractions of 10 Gy HDRBT at a single centre, 2002–2008, still alive at five years. As part of routine follow-up, the patients responded to the EORTC QLQ-C30 and PR-25 questionnaires. Cohort B: HRQoL data was retrieved from an earlier study from the original article. In Cohort A, 1046 (70%) men completed the questionnaires at five years, median age 66 years. In general, HRQoL mean scores were high and similar to Swedish age-matched normative data. Concerning disease-specific HRQoL, low levels of bowel and urinary problems were reported, in contrast to a substantial effect on sexual functioning. ‘No’ or ‘A little’ problems with faecal incontinence and urinary incontinence were reported by 98% and 93% of patients, respectively. The corresponding figure for sexual functioning was 39%. A difference in the frequency of nocturia in favour of Cohort A was the only statistically significant difference between Cohort A and B found in general and disease-specific HRQOL (p = 0.03), despite modifications in the brachytherapy procedure introduced in 2001. Long-term general HRQoL was rated high and comparable to an aged-matched reference population five years after treatment with combined radiotherapy. Disease-specific HRQoL was still affected, foremost in the sexual domain.</p

Prostate cancer (PC) knowledge by participation to risk-based PC screening, three months before invitation to screening.

<p>Prostate cancer (PC) knowledge by participation to risk-based PC screening, three months before invitation to screening.</p

Men’s worry and perceived vulnerability to prostate cancer (PC) by participation to risk-based PC screening, three months before invitation to screening.

<p>Men’s worry and perceived vulnerability to prostate cancer (PC) by participation to risk-based PC screening, three months before invitation to screening.</p

Health behaviour scale scores by participation to risk-based PC screening, three months before invitation to screening.

<p>Health behaviour scale scores by participation to risk-based PC screening, three months before invitation to screening.</p

High rate of local control and cure at 10 years after treatment of prostate cancer with external beam radiotherapy and high-dose-rate brachytherapy: a single centre experience

To analyse the cumulative incidence of any failure (AF), prostate cancer-specific failure (PCSF), any death (AD), prostate cancer-specific death (PCSD), and local control in 2387 men with prostate cancer (PC), consecutively treated with combined high-dose-rate brachytherapy (HDRBT) and external beam radiotherapy (EBRT) from 1998 to 2010. A retrospective, single-institution study of men with localised PC. The mean age was 66 years and 54.7% had high-risk PC according to the Cambridge prognostic group (CPG) classification. The treatment was delivered as EBRT (2 Gy × 25) and HDRBT (10 Gy × 2) with combined androgen blockade (CAB). The median follow-up was 10.2 years. The cumulative incidence of PCSD at 10 years was 5% [CI 95% 0.04–0.06]. The 10 years PCSD per risk group were: low (L) 0.4%, intermediate favourable (IF) 1%, intermediate unfavourable (IU) 4.3%, high-risk favourable (HF) 5.8%, and high-risk unfavourable (HU) 13.9%. The PCSF rate at 10 years was 16.5% [CI 95% 0.15–0.18]. The PCSF per risk group at 10 years were: L 2.5%, IF 5.5%, IU 15.9%, HF 15.6%, and HU 38.99%. PCSF occurred in 399 men, of whom 15% were found to have local failure. The estimated frequency of local failure in the entire cohort was 1.2%. HDRBT combined with EBRT is an effective treatment with long-term overall survival and excellent local control for patients with PC. The low rate of local recurrence among men with relapse suggests that these patients were micro metastasised at time of treatment, which calls for improved methods to detect disseminated disease.</p

Mean quality of life scores.

<p>Note: For global health/quality of life and the functional scales a higher score indicates a better quality of life, whereas for the symptom scales/items a lower score indicates a better quality of life. For the continuous variables (i.e. global health/quality of life; emotional functioning; cognitive functioning; fatigue; pain; dyspnoea; and insomnia) mean scores (SD) are presented. For the dichotomized scales (i.e. physical functioning; role functioning; social functioning; nausea and vomiting; appetite loss; constipation; diarrhea; financial difficulties) frequencies and percentages for the category with the highest quality of life is provided. Please note that for 6, 3, 10, 1, 0, 6, 5, 3, 2, 13, 4, 3, 2, 4, 7 participants respectively information was missing.</p><p>^a = cognitive functioning was transformed by using square root transformation [√(101-raw score)], ranging from 1–10 with low scores having a better cognitive functioning. The transformed mean score and standard deviation is 2.9 (2.4).</p><p>Mean quality of life scores.</p

Relation between quality of life and the single nucleotide polymorphisms selected by physical annotation (n = 10,649).

<p>Note: For the 139 candidate genes, 10,649 SNPs were selected based on physical annotation (build 37). Bonferonni corrected p-value = 3.76E-06 (0.05/2,663+10,649 SNPs). For the continuous variables (i.e. global health/quality of life; emotional functioning; cognitive functioning; fatigue; pain; dyspnoea; and insomnia) linear regressions were performed. For the dichotomized variables (i.e. physical functioning; role functioning; social functioning; nausea and vomiting; appetite loss; constipation; diarrhea; financial difficulties) we used logistic regression analyses. Chr = chromosome; Position = position of the chromosome; Minor/major = minor and major alleles based on forward strand and minor allele frequencies in Europeans; MAF = minor allele frequency over all European controls in iCOGS; Beta = beta value for the minor allele relative to the major allele; SE = standard error; p = p-value.</p><p>^a = cognitive functioning was transformed by using square root transformation [√(101-raw score)] ranging from 1–10, with low scores having a better cognitive functioning, therefore the direction of the relation is reversed.</p><p>Relation between quality of life and the single nucleotide polymorphisms selected by physical annotation (n = 10,649).</p

Additional file 2 of Whole-body MRI within a surveillance program for carriers with clinically actionable germline TP53 variants - the Swedish constitutional TP53 study SWEP53

Additional file 2. Standardised protocol for evaluation of whole-body MRI within SWEP53